Evidence map›Paper›PMID 41527663›Full record

ReviewAIMS neuroscience2025

Preclinical evidence and therapeutic perspectives on carnosine for the treatment of neurodegenerative disorders.

Saviana Antonella Barbati, Giuseppe Carota, Konstantinos Partsinevelos, Lucia Di Pietro, Anna Privitera, Vincenzo Cardaci, Andrea Graziani, Renata Mangione, Giuseppe Lazzarino, Barbara Tavazzi and 7 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in AIMS neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Saviana Antonella BarbatiDepartmental Faculty of Medicine, UniCamillus-Saint Camillus International University of Health Sciences, Rome, Italy.
Giuseppe CarotaDepartment of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy.
Konstantinos PartsinevelosDepartment of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy.
Lucia Di PietroDepartment of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy.
Anna PriviteraDepartment of Biological, Geological and Environmental Science, University of Catania, Catania, Italy.
Vincenzo CardaciUniversità Vita-Salute San Raffaele, Milano, Italy.
Andrea GrazianiDepartmental Faculty of Medicine, UniCamillus-Saint Camillus International University of Health Sciences, Rome, Italy.
Renata MangioneDepartmental Faculty of Medicine, UniCamillus-Saint Camillus International University of Health Sciences, Rome, Italy.
Giuseppe LazzarinoLTA-Biotech srl, Paternò, Catania, Italy.
Barbara TavazziDepartmental Faculty of Medicine, UniCamillus-Saint Camillus International University of Health Sciences, Rome, Italy.
Valentina Di PietroSchool of Infection, Inflammation & Immunology, Department of Inflammation and Ageing, College of Medicine and Health, University of Birmingham, Birmingham, United Kingdom.
Emiliano MaianiDepartmental Faculty of Medicine, UniCamillus-Saint Camillus International University of Health Sciences, Rome, Italy.
Francesco BelliaDepartment of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy.
Angela Maria AmoriniDepartment of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy.
Giacomo LazzarinoDepartmental Faculty of Medicine, UniCamillus-Saint Camillus International University of Health Sciences, Rome, Italy.
Shahid Pervez BabaCenter for Cardiometabolic Science, Louisville, KY, USA.
Giuseppe CarusoDepartmental Faculty of Medicine, UniCamillus-Saint Camillus International University of Health Sciences, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Carnosine (β-alanyl-L-histidine) is an endogenous dipeptide widely distributed in mammalian tissues, especially skeletal and cardiac muscle cells, and, to a lesser extent, in the brain. While early interest in carnosine was given because of its role in muscle cell metabolism and athletic performance, it has more recently gained attention for its potential application in several chronic diseases. Specifically, brain aging and neurodegenerative disorders have received particular attention, as a marked reduction in carnosine levels has been described in these conditions. Carnosine exerts a wide range of biological activities, including antioxidant, anti-inflammatory, anti-glycation, metal-chelating, and neuroprotective properties. Mechanistically, it acts by inhibiting the production of advanced glycation end products (AGEs), buffering cellular pH, and regulating intracellular nitric oxide signaling and mitochondrial function. Its safety profile, the lack of toxicity, and significant side effects support its application for long-term therapeutic use. In this review, we aim to recapitulate and discuss the effects, dosages, and administration routes of carnosine in preclinical

Indexed as

Alzheimer's diseaseanimal modelscarnosinecarnosinemiacellular and molecular mechanismsin vivo studiesParkinson's diseasestroke

Identifiers

PMID41527663
PMCPMC12790938

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.